Polycystic Ovary Syndrome (PCOS)
Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
This study will assess the potential impact of Elagolix on disordered pituitary and ovarian hormones in women with Polycystic Ovary Syndrome (PCOS).
Study Length: 8 to 9 months
Target Age/Sex: 18 Years to 35 Years, Female
Participants will receive at no cost: Study medication and study related procedures. Subject may also receive a stipend for time/travel related to the study.